Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type

Guidance programme 1 selected

Guidance programme

Area of interest

Showing 111 to 120 of 903

TitleReference numberPublishedLast updated
Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A in people 2 years and overTA1051
Pegylated liposomal irinotecan in combination for untreated metastatic pancreatic cancer (terminated appraisal)TA1052
Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after first-line chemoimmunotherapy when a stem cell transplant is suitableTA1048
Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive minimal residual disease-negative B-cell precursor acute lymphoblastic leukaemiaTA1049
Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and overTA1050
Zolbetuximab with chemotherapy for untreated claudin-18.2-positive HER2-negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinomaTA1046
Atezolizumab for untreated advanced or recurrent non-small-cell lung cancer when platinum-doublet chemotherapy is unsuitable (terminated appraisal)TA1047
12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mitesTA1045
Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resectionTA1043
Exagamglogene autotemcel for treating severe sickle cell disease in people 12 years and overTA1044

Results per page

  1. 10
  2. 25
  3. 50
  4. All